Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome

The aim of our trial was to evaluate the prognostic significance of qualitative ctDNA analysis on different stages of EGFR mutated non-small cell lung cancer (NSCLC) treatment.We included 99 patients amendable for the first line treatment with either gefitinib/erlotinib (n = 87), afatinib (n = 10) o...

Full description

Saved in:
Bibliographic Details
Main Authors: F.V. Moiseenko, N.M. Volkov, A.S. Zhabina, M.L. Stepanova, N.A. Rysev, V.V. Klimenko, A.V. Myslik, E.V. Artemieva, V.V. Egorenkov, N.H. Abduloeva, A.O. Ivantsov, E.S. Kuligina, E.N. Imyanitov, V.M. Moiseyenko
Format: Artigo
Language:Inglês
Published: Elsevier 2022-01-01
Series:Cancer Treatment and Research Communications
Subjects:
NSCLC
EGFR
Targeted therapy
ctDNA
Prognosis
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294222000132
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items